Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
Barnes Group Inc. operates as an international industrial and aerospace manufacturer, making its news coverage relevant for investors tracking manufacturing sector developments and aerospace industry dynamics. The company's two-segment structure means news can reflect either industrial market conditions or aerospace sector trends, providing insight into different economic drivers.
Industrial segment news typically covers manufacturing activity, automotive production trends, capital equipment demand, and customer order patterns. Announcements may address precision component applications, automation technology developments, or contract wins with industrial equipment manufacturers. These updates help investors understand how manufacturing cycles and industrial production levels affect the company's business performance.
Aerospace segment coverage focuses on engine component contracts, original equipment manufacturer relationships, and aftermarket service demand. News may include updates on aviation production rates, commercial aircraft deliveries, defense program participation, or maintenance service contract awards. The aerospace business generates news tied to long-term aviation trends rather than short-term market fluctuations, reflecting the extended product cycles characteristic of aerospace manufacturing.
Earnings reports provide quarterly insight into both segment performances, revealing how industrial and aerospace markets contribute to overall results. Financial news also covers operational metrics like margins, order backlogs, and geographic revenue distribution across the company's international footprint. Investors following Barnes Group track these reports to assess how different market conditions affect each business segment.
Corporate development news may address acquisitions of complementary manufacturing capabilities, facility expansions, operational efficiency initiatives, or strategic investments in manufacturing technology. The company's focus on precision manufacturing and technical capabilities makes technology adoption and process improvement announcements particularly relevant for understanding competitive positioning.
This news page aggregates Barnes Group announcements and market coverage in one location, allowing investors to monitor developments across both the Industrial and Aerospace segments. Bookmark this page to track how manufacturing cycles, aerospace demand, and operational initiatives shape this precision component manufacturer's business trajectory.
Barrick (NYSE:B) announced on November 10, 2025 that its Board approved a $500 million increase to the existing share repurchase program.
In February 2025 the Board authorized repurchases up to $1.0 billion over 12 months; Barrick had repurchased $1.0 billion of shares as of September 30, 2025. The additional $500 million allows for potential further repurchases over the remaining term of the program. Repurchases may occur on public U.S. markets, including the NYSE, and by other SEC‑permitted methods. The Company said actual timing and amounts will depend on financial performance, cash flow availability, capital needs, other shareholder returns, and debt reduction, and that the program may be suspended at any time. The Board will consider any 2026 program in February 2026.
B (Barrick) raised its quarterly base dividend by 25% to $0.125 per share and declared an enhanced Q3 2025 dividend of $0.175 per share (including a $0.05 performance dividend). The Q3 dividend is payable on December 15, 2025 to holders of record on November 28, 2025. Barrick repurchased approximately 18.60 million shares in Q3 and 39.79 million shares year-to-date under the 2025 buyback program, representing about 2.3% of issued shares, for total cash of $1.0 billion (including $589 million in Q3). The company updated its Performance Dividend Policy showing tiered performance payments up to $0.15 per quarter, producing a maximum quarterly total of $0.275 per share.
Cereno Scientific (B) submitted the clinical trial protocol for a planned global Phase IIb study of CS1 in pulmonary arterial hypertension (PAH) to the U.S. FDA on Nov 10, 2025. The submission follows FDA Type C meeting feedback and aims to advance CS1—an oral HDAC inhibitor that targets PAH via epigenetic modulation—after Phase IIa showed favorable safety, tolerability and encouraging efficacy signals (reverse vascular remodeling, improved right heart function, better patient quality of life). The Phase IIb is designed as a global, multicenter, placebo-controlled trial run with an international CRO. Cereno expects the FDA's standard 30-day review and plans to start the trial in H1 2026.
B (Barrick) completed the sale of the Alturas Project in Chile to Boroo Pte. Ltd. for an up-front cash payment of $50 million on Nov 7, 2025. Barrick also retained a 0.5% net smelter return (NSR) royalty on gold and silver from the project that terminates after 2 million ounces gold-equivalent are produced. Boroo has a four-year repurchase option to buy back the royalty for $10 million. The transaction converts the asset to cash and a capped royalty interest.
Helzberg (NYSE:A) will open redesigned stores in New York and Dallas in November 2025, unveiling next‑generation brick-and-mortar concepts that combine digital discovery with hands-on craftsmanship. The new stores feature an interactive custom bar, a visible jeweler's workshop, a larger diamond carat-weight assortment in engagement rings and wedding bands, and an expanded Luxe Jewelry collection.
A company consumer study found 83% of couples say the ability to purchase in-store is important, nearly three in five plan to consult a jeweler and buy in person, 47% rate ring customization as very important, and 76% would invest more in a custom design. Helzberg also highlights digital support via its Love & Marriage Studio for pre-visit education and inspiration.
Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.
Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.
Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.
BioArctic (Nasdaq Stockholm: B) will publish its third quarter report for July–September 2025 on Thursday, 13 November 2025 at 08:00 CET. An English-language audiocast with teleconference will follow the report on 13 November 2025 at 09:30 CET, where CEO Gunilla Osswald and CFO Anders Martin-Löf with colleagues will present the report and hold a Q&A.
Investors, analysts and media can join via webcast (written questions) or teleconference (verbal questions) after registration. The webcast will be available on demand on BioArctic's investor website. Contact: Oskar Bosson, VP Communications and Investor Relations.
Crawford & Company (NYSE: CRD-A, CRD-B) announced that on October 30, 2025 its Board authorized an additional 2.0 million shares under its existing share repurchase program and extended the program termination to December 31, 2027. The repurchase program, originally approved November 4, 2021 and increased February 10, 2022, had authorized up to an aggregate of seven million common shares; as of October 30, 2025 only 634,920 shares remained under that authorization. Repurchases may occur in the open market or via privately negotiated transactions and are discretionary. The Board also declared a quarterly dividend of $0.075 per share, payable December 5, 2025 to shareholders of record as of November 19, 2025.
Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).
The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.
FAQ
What is the current stock price of Barrick Mining Corporation (B)?
What is the market cap of Barrick Mining Corporation (B)?
